Thioredoxin 1 as a serum marker for breast cancer and its use in combination with CEA or CA15-3 for improving the sensitivity of breast cancer diagnoses

BMC Research Notes

Il-Han Kim¹  Mee-Kyung Cha¹  Byung-Joon Park¹ 

[1] Department of Life Sciences & Technology, Paichai University, Daeduk Campus, Techno 1Ro, Daejeon, Republic of Korea

关键词: Reactive oxygen species;    Cancer antigen 15–3 (CA15-3);    Carcinoembryonic antigen (CEA);    Companion marker;    Thioredoxin 1;    Diagnosis;    Breast cancer;   

Others  :  1134990
DOI  :  10.1186/1756-0500-7-7

 received in 2013-03-08, accepted in 2014-01-03,  发布年份 2014

【 摘 要 】

Background

The human cytosolic thioredoxin (Trx) contains a redox-active dithiol moiety in its conserved active-site sequence. Activation by a wide variety of stimuli leads to secretion of this cytoplasmic protein. Function of Trx1 has been implicated in regulating cell proliferation, differentiation, and apoptosis. The aim of this study was to assess the clinical significance of serum Trx1 level in patients with breast carcinoma.

Results

To clarify whether serum levels of Trx1 could be a serum marker for breast carcinoma, we measured the serum levels of Trx1 in patients with various carcinomas (breast, lung, colorectal, and kidney cancers) using an ELISA, and investigated its associations with the tumour grading from I to III. At the cut-off point 33.1725 ng/ml on the receiver operating characteristic curve (ROC) Trx1 could well discriminate breast carcinoma from normal controls with a sensitivity of 89.8%, specificity 78.0%, and area under the ROC (AUC) 0.901 ± 0.0252. The serum level was well correlated with the progress of the breast carcinoma. We also investigated the diagnostic capacity of CEA and CA15-3 for the early detection of metastatic breast cancer comparing that of Trx1. In contrast to the serum CEA and CA15-3 tumour markers, the serum Trx1 levels of the early cancer (grade I) patients were significantly higher than those of normal control subjects, showing a high diagnostic sensitivity and selectivity (89.4% sensitivity, and 72.0% specificity). The serum levels of Trx1 in various patients with lung, colorectal, and kidney carcinomas indicate that the level of Trx1 is significantly higher than those of other cancer patients. Combinational analysis of CEA or CA15-3 with Trx1 for the detection of breast cancer suggest that the diagnostic capacity of CEA or CA15-3 alone for the early detection of breast cancer, especially regarding sensitivity, is significantly improved by its combination with Trx1.

Conclusions

Taken together, we conclude that serum Trx1 is useful for the early diagnosis of breast cancer or the early prediction prognosis of breast cancer, and therefore has a valuable use as a diagnostic marker and companion marker to CEA and CA15-3 for breast cancer.

【 授权许可】

   
2014 Park et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

【 参考文献 】

• [1]Sundaresan M, Yu ZX, Ferrans VJ, Irani K, Finkel T: Requirement for generation of H2O2 for platelet-derived growth factor signal transduction. Science 1995, 270:296-299.
• [2]Finkel T: Oxygen radicals and signaling. Curr Opin Cell Biol 1998, 10:248-253.
• [3]Kang SW, Chae HZ, Seo MS, Kim K, Baines IC, Rhee SG: Mammalian peroxiredoxin isoforms can reduce hydrogen peroxide generated in response to growth factors and tumor necrosis factor-alpha. J Biol Chem 1998, 273:6297-6302.
• [4]Chae HZ, Robison K, Poole LB, Church G, Storz G, Rhee SG: Cloning and sequencing of thiol-specific antioxidant from mammalian brain, alkyl hydroperoxide reductase and thiol-specific antioxidant define a large family of antioxidant enzymes. Proc Natl Acad Sci U S A 1994, 91:7017-7021.
• [5]Schumacker PT: Reactive oxygen species in cancer cells: live by the sword, die by the sword. Cancer Cell 2006, 10:175-176.
• [6]Trachootham D, Zhou Y, Zhang H, Demizu Y, Chen Z, Pelicano H, Chiao PJ, Achanta G, Arlinghaus RB, Liu J, Huang P: Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by beta-phenylethyl isothiocyanate. Cancer Cell 2006, 10:241-252.
• [7]Mitsui A, Hirakawa T, Yodoi J: Reactive oxygen-reducing and protein-refolding activities of adult T cell leukemia-derived factor/human thioredoxin. Biochem Biophys Res Commun 1992, 186:1220-1226.
• [8]Ohira A, Honda O, Gauntt CD, Yamamoto M, Hori K, Masutani H, Yodoi J, Honda Y: Oxidative stress induces adult T cell leukemia derived factor/thioredoxin in the rat retina. Lab Invest 1994, 70:279-285.
• [9]Nakamura H, Matsuda M, Furuke K, Kitaoka Y, Iwata S, Toda K, Inamoto T, Yamaoka Y, Ozawa K, Yodoi J: Adult T cell leukemia-derived factor/human thioredoxin protects endothelial F-2 cell injury caused by activated neutrophils or hydrogen peroxide. Immunol Lett 1994, 42:75-80.
• [10]Sasada T, Iwata S, Sato N, Kitaoka Y, Hirota K, Nakamura K, Nishiyama Taniguchi A, Takabayashi A, Yodoi J: Redox control of resistance to cis-diamminedichloroplatinum (II) (CDDP): Protective effect of human thioredoxin against CDDP-induced cytotoxicity . J Clin Invest 1996, 97:2268-2276.
• [11]Schenk H, Klein M, Erdbrugger W, Droge W, Schulze OK: Distinct effects of thioredoxin and antioxidants on the activation of transcription factors NF-κB and AP-1. Proc Natl Acad Sci USA 1994, 91:1672-1676.
• [12]Makino Y, Okamoto K, Yoshikawa N, Aoshima M, Hirota K, Yodoi J, Umesono K, Makino I, Tanaka H: Thioredoxin: A redox-regulating cellular cofactor for glucocorticoid hormone action: crosstalk between endocrine control of stress response and cellular antioxidant defense system. J Clin Invest 1995, 98:2469-2477.
• [13]Ueno M, Masutani H, Arai AJ, Yamauchi A, Hirota K, Sakai T, Inamoto T, Yamaoka J, Yodoi J, Nikaido T: Thioredoxin-dependent redox regulation of p53-mediated p21 activation. J Biol Chem 1999, 274:35809-35815.
• [14]Hayashi S, Hajiro NK, Makino Y, Eguchi H, Yodoi Y, Tanaka H: Functional modulation of estrogen receptor by redox state with reference to thioredoxin as a mediator. Nucleic Acids Res 1997, 25:4035-4040.
• [15]Arner ES, Holmgren A: The thioredoxin system in cancer. Semin Cancer Biol 2006, 16:420-426.
• [16]Matsutani Y, Yamauchi A, Takahashi R, Ueno M, Yoshikawa K, Honda K, Nakamura H, Kato H, Kodama H, Inamoto T, Yodoi J, Yamaoka Y: Inverse correlation of thioredoxin expression with estrogen receptor- and p53-dependent tumor growth in breast cancer tissues. Clin Cancer Res 2001, 7:3430-3436.
• [17]Nakamura H, Masutani H, Tagaya Y, Yamauchi A, Inamoto T, Nanbu Y, Fujii S, Ozawa K, Yodoi Y: Expression and growth-promoting effect of adult T-cell leukemia-derived factor: a human thioredoxin homologue in hepatocellular carcinoma. Cancer 1992, 69:2091-2097.
• [18]Fujii S, Nanbu Y, Nonogaki H, Konishi I, Mori T, Masutani H, Yodoi Y: Coexpression of adult T-cell leukemia-derived factor, a human thioredoxin homologue, and human papillomavirus DNA in neoplastic cervical squamous epithelium. Cancer 1991, 68:1583-1591.
• [19]Kobayashi F, Sagawa N, Nanbu Y, Kitaoka Y, Mori T, Fujii S, Nakamura H, Masutani H, Yodoi Y: Biochemical and topological analysis of adult T-cell leukaemia-derived factor, homologous to thioredoxin, in the pregnant human uterus. Hum Reprod 1995, 10:1603-1608.
• [20]Allemani C, Sant M, Weir HK, Richardson LC, et al.: Breast cancer survival in the US and Europe: a CONCORD high-resolution study. Int J Cancer 2013, 132:1170-1181.
• [21]Cha MK, Suh KH, Kim IH: Overexpression of peroxiredoxin I and thioredoxin1 in human breast carcinoma. Exp Clin Cancer Res 2009, 28:93. doi: 10.1186/1756-9966-28-93 BioMed Central Full Text
• [22]Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, Somerfield MR, Hayes DF, Bast RC Jr: American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer. J Clin Oncol 2007, 25:5287-5312.
• [23]Gold P, Freedman SO: Demonstration of tumor-specific antigens in human colonic carcinomata by immunological tolerance and absorption techniques. J Exp Med 1965, 121:439-462.
• [24]Hammarström S: The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues. Semin Cancer Biol 1999, 9:67-81.
• [25]Maestranzi S, Przemioslo R, Mitchell H, Sherwood RA: The effect of benign and malignant liver disease on the tumour markers CA19-9 and CEA. Ann Clin Biochem 1998, 35:99-103.
• [26]Thomas SN, Zhu F, Schnaar RL, Alves CS, Konstantopoulos K: Carcinoembryonic antigen and CD44 variant isoforms cooperate to mediate colon carcinoma cell adhesion to E- and L-selectin in shear flow. J Biol Chem 2008, 283:15647-15655.
• [27]Duffy MJ, Van Dalen A, Haglund C, Hansson L, Klapdor R, Lamerz R, Nilsson O, Sturgeon C, et al.: Clinical utility of biochemical markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines. Eur J Cancer 2003, 39:718-727.
• [28]Jelski W, Chrostek L, Szmitkowski M, Markiewicz W: The activity of class I, II, III and IV alcohol dehydrogenase isoenzymes and aldehyde dehydrogenase in breast cancer. Clin Exp Med 2006, 6:89-93.
• [29]Jelski W, Chrostek L, Markiewicz W, Szmitkowski M: Activity of alcohol dehydrogenase (ADH) isoenzymes and aldehyde dehydrogenase (ALDH) in the sera of patients with breast cancer. J Clin Lab Anal 2006, 20:105-108.